Novartis Pauses Autoimmune Cell Therapy Studies Following Patient Deaths

Novartis has temporarily halted eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders after three patients died. The deaths were linked to a severe immune response, a known safety risk in CAR-T therapies. The company is conducting a comprehensive review and collaborating with independent safety boards and regulators.